Zynyz® (retifanlimab-dlwr) – New indication
May 15, 2025 - Incyte announced the FDA approval of Zynyz (retifanlimab-dlwr) in combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal; as a single agent, for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
Top